Our findings demonstrated altered DNA methylation in subjects with MetS, suggesting that GFPT2 hypermethylation might be a promising epigenetic biomarker and emphasizing the role of aberrant GFPT2 expression in MetS pathogenesis. The gene discussed is GFPT2; the disease is metabolic syndrome.